Abstract | PURPOSE: METHODS: RESULTS: The average number of injections over 5 years was 4.56 ± 3.52. Ten eyes (55.56%) had no need for treatment after the first year. Mean best-corrected visual acuity improved from 0.59 ± 0.47 logarithm of the minimum angle of resolution (Snellen equivalent, 6/24) at baseline to 0.32 ± 0.35 logarithm of the minimum angle of resolution (Snellen equivalent, 6/13) at 1 year, and to 0.38 ± 0.42 logarithm of the minimum angle of resolution (Snellen equivalent, 6/15) at 2 years (P = 0.001 and 0.020, respectively; paired t-test). After 2 years, although mean best-corrected visual acuity remained better than baseline, the difference was not statistically significant. At 5 years, vision improved by at least 1 line for 61.11% of eyes and by more than 3 lines for 33.33%. The final visual acuity of 2 eyes was worse than baseline because of disease activity and profound chorioretinal atrophy, which increased in six eyes. No complications were noted. CONCLUSION:
|
Authors | Tsung-Tien Wu, Ya-Hsin Kung |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 37
Issue 11
Pg. 2056-2061
(Nov 2017)
ISSN: 1539-2864 [Electronic] United States |
PMID | 28590318
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Vascular Endothelial Growth Factor A
- Ranibizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage)
- Choroidal Neovascularization
(diagnosis, drug therapy, etiology)
- Dose-Response Relationship, Drug
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Fundus Oculi
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Myopia, Degenerative
(complications, physiopathology)
- Ranibizumab
(administration & dosage)
- Refraction, Ocular
- Retreatment
- Retrospective Studies
- Time Factors
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(drug effects)
- Young Adult
|